Summary
The symptomatic effects of felodipine (PlendilR) have been assessed in 10 patients with primary Raynaud's phenomenon in a single blind study. After 2 weeks on placebo, the patients were treated for 6 weeks with felodipine, the dose being titrated stepwise every 2 weeks, starting with 5 mg, and increasing to 10 mg and 20 mg once daily if symptoms persisted. After the drug period the patients received placebo for 2 weeks.
Objective measurement by cold exposure finger plethysmography did not show any benefit of felodipine in the higher temperature range, taking 33°C as reference point. However, when using 24°C as the reference point, the area under the plethysmography versus temperature curve (AUC) for 5 mg felodipine were significantly larger than the initial placebo area. The AUC during recovery from cold exposure for the maximal accepted dose of felodipine was significantly larger than for the initial placebo period.
Subjective judgement by the patients showed a significant reduction in the number of Raynaud attacks and a trend to a shorter duration of attacks with the maximal dose of felodipine. Two patients became free from attacks of Raynaud's phenomenon. Felodipine 10 mg once daily was well tolerated. It was regarded as the optimal dose to treat patients with Raynaud's symptoms.
References
Smith CR, Rodeheffer RJ (1985) Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers. Am J Cardiol 55: 154B-157B
Freedman RR, Ianni P (1983) Role of cold and emotional stress in Raynaud's disease and scleroderma. Br Med J 297: 1499–1502
Roath S (1989) Managing Raynaud's phenomenon. Drugs 37: 700–712
Wesseling H (1987) Drug treatment in Raynaud's phenomenon, VASA 18 [Suppl]: 48–53
Cooke ED, Nicolaides AN (1990) Raynaud's syndrome. Thymoxamine, iloprost and ACE inhibitors are among the effective treatments now available. Br Med J 300: 553–555
Kinney EL, Nicholas GG, Gallo J, Pontoriero C, Zelis R (1982) The treatment of severe Raynaud's phenomenon with verapamil. J Clin Pharmacol 22: 74–76
Kahan A, Amor B, Menkes CJ (1985) A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Ann Rheum Dis 44: 30–33
Gjorup Th, Kelboek H, Hartling OJ (1986) Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon. Am Heart J 111: 742–745
Waller DG, Challenor VF, Francis DA, Roath OS (1986) Clinical and rheological effects of nifedipine in Raynaud's phenomenon. Br J Clin Pharmacol 22: 449–454
Kallenberg CGM, Wouda AA, Kuitert JJ, Tijssen J, Wesseling H (1987) Nifedipine in Raynaud's phenomenon: Relationship between immediate, short term and long term effects. J Rheumatol 14: 284–290
Ljung B (1985) Vascular selectivity of felodipine. Drugs 29 [Suppl 2]: 46–58
Wouda AA (1977) Raynaud's phenomenon. Photoelectric plethysmography of the fingers of persons with and without Raynaud's phenomenon during cooling and warming up. Acta Med Scand 201: 519–523
Schmidt JF, Valentin N, Levin Nielsen S (1989) The clinical effect of felodipine and nifedipine in Raynaud's phenomenon. Eur J Clin Pharmacol 37: 191–192
Dunselman PHJM (1989) Felodipine in congestive heart failure. Pharmacokinetic, pharmacodynamic, hemodynamic and clinical aspects. Thesis Groningen, the Netherlands
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kallenberg, C.G.M., Wouda, A.A., Meems, L. et al. Once daily felodipine in patients with primary Raynaud's phenomenon. Eur J Clin Pharmacol 40, 313–315 (1991). https://doi.org/10.1007/BF00315217
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315217